Install
Clinical Trials (Phases I–IV)
Design, endpoints, enrollment, interim reads, and post‑market surveillance.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Clinical Trials (Phases I–IV)
Asthma Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Therapeutics Landscape
5+ hour, 9+ min ago (63+ words) Asthma Clinical Trial Pipeline: DelveInsight Highlights Major openPR.com Asthma Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Therapeutics Landscape Press release from: ABNewswire Permanent link to this press release: You can edit or…...
OS Therapies Aligns With FDA on Phase 3 Design, Accepts MHRA's Project Orbis Invitation for OST-HER2
7+ hour, 19+ min ago (675+ words) BioBuzz OS Therapies Aligns With FDA on Phase 3 Design, Accepts MHRA’s Project Orbis Invitation for OST-HER2 OS Therapies, Inc., a Rockville, Maryland- and New York-based clinical-stage oncology company, announced on September 17, 2026 that it has achieved incremental alignment with the FDA…...
B-Cell Non-Hodgkin Lymphoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight
5+ hour, 13+ min ago (59+ words) B-Cell Non-Hodgkin Lymphoma Clinical Trial Pipeline: Emerging openPR.com B-Cell Non-Hodgkin Lymphoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight Press release from: ABNewswire Permanent link to this press release: You can edit or delete…...
Cue’s anti-IgE antibody CUE-221 meets Phase II endpoints in chronic urticaria
13+ hour, 14+ min ago (648+ words) AllSci CUE-221 (UB-221), a dual-mechanism anti-IgE monoclonal antibody being developed by Boston-based Cue Biopharma (Nasdaq: CUE), met both its primary and key secondary endpoints in a Phase II study in chronic spontaneous urticaria (CSU), according to topline results released September…...
Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial
15+ hour, 36+ min ago (90+ words) Cue Biopharma’s potential Xolair challenger passes Phase 2 chronic hives trial Endpoints News Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial Cue Biopharma said Sunday its chron…...
Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients
6+ day, 9+ hour ago (758+ words) Sep 15, 2026, 12:46 ET BOSTON, Sept. 15, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, today announced final fifteen-month results from its Phase 1/2 clinical trial evaluating SKY-0515, an investigational oral treatment for Huntington's…...
Definium’s LSD therapy posts second positive Phase III GAD result
6+ day, 10+ hour ago (136+ words) DT120 ODT 100 µg produced a least squares mean HAM-A change of −9.8 versus −4.7 for placebo, a placebo-adjusted difference of −5.1 points (p The 50 µg exploratory arm produced a placebo-adjusted HAM-A reduction of approximately 3.5-3.6 points at Weeks 4 and 12 — roughly 50% and 29% lower than the 100 µg arm,…...
Definium Reports Second Phase III Success in Anxiety Disorder Program
6+ day, 11+ hour ago (353+ words) Year to date, Definium stock has skyrocketed 200.6% against the industry's 2.9% decline. Beyond GAD, Definium is advancing DT120 ODT in major depressive disorder (MDD). DFTX's phase III Emerge study delivered positive top-line results in June 2026, meeting its primary and key secondary endpoints. The…...
H. Lundbeck A/S (OMXCOP:HLUN_A) Completes Randomization in Phase III Dravet Trial
6+ day, 18+ hour ago (128+ words) TradingView H. Lundbeck A/S (OMXCOP:HLUN_A) Completes Randomization in Phase III Dravet Trial H. Lundbeck A/S said the last patient has been randomized in DEEp SEA, a global Phase III trial of bexicaserin for seizures in Dravet syndrome; over 100 participants enrolled,…...
A Single Dose of Pharmaceutical LSD Cut Anxiety Scores Five Points Below Placebo in Phase 3 Trial
1+ week, 2+ hour ago (773+ words) A single dose of a pharmaceutical formulation of LSD cut anxiety scores by about 5 points more than placebo over 12 weeks, according to topline results from the Panorama study released Monday by Definium Therapeutics. Panorama enrolled 245 adults with generalized anxiety disorder…...